Clinical study of pirenpanet as add-on therapy for intractable epilepsy_Journal of Epilepsy

Authors：

HAN Xiangyu , TAO Deshuang , WU Dan , HOU Zhengping ,  WANG Juli

Department of Neurology, Jiamusi Center Hospital, Jiamusi 154002, China;

Corresponding?author：

WANG Juli, Email: wjl198981@163.com

Keywords：

Pirenpanet; Refractory epilepsy; Clinical study

DOI：

10.7507/2096-0247.202303003

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To observe the efficacy and adverse reactions of pirenpanet in patients with refractory epilepsy treated with add-on therapy. Methods Forty-one patients with medically refractory epilepsy were selected from January 2021 to December 2021 in the Department of Epilepsy of Jiamusi Central Hospital, among which 25 males and 16 females. The self-control study was conducted before and after the treatment with pirenpanet. The observation period was 1 year, and the clinical efficacy, platelet, liver and kidney function and EEG discharge index were observed at 6 months and 12 months respectively. Changes in seizure frequency after treatment were divided into the following 3 groups: effective control: no seizure; effective: seizures reduced by 50% ~ 99%; Ineffective: < 50% reduction in seizures or exacerbation. Results Among the 41 patients with drug-refractory epilepsy, 8 (8/41, 19.51% P < 0.05) were seizure-free, 17 (17/41, 41.46% P < 0.05) were effective, and the total effective rate was (25/41, 60.98%); Sixteen cases (16/41, 39.02%) were ineffective. There were 31 children in 41 cases (31/41, 75.61%), of which 18 cases (18/31, 58.06%) were effective, 16 cases (16/31, 51.61%) had mental and motor retardation, and 8 cases (8/16, 50%) were effective; There were 10 adults (10/41, 24.39%) and 7 effective patients (7/10, 70%). After one year's treatment, the EEG changes of the patients were observed, and the abnormal discharge of 6 patients was reduced according to the discharge index, 2 patients had no abnormal discharge, and the other patients had no obvious EEG changes. Conclusion Pirenpanet is effective and safe as an add-on therapy for medically refractory epilepsy.

Citation： HAN Xiangyu, TAO Deshuang, WU Dan, HOU Zhengping, WANG Juli. Clinical study of pirenpanet as add-on therapy for intractable epilepsy. Journal of Epilepsy, 2023, 9(5): 382-387. doi: 10.7507/2096-0247.202303003 Copy

1.	Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51(6): 1069-1077.
2.	Fergus Rugg-Gunn. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia, 2014, 1: 13-15.
3.	JA French, GL Krauss, V Biton, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology, 2012, 79(6): 589-596.
4.	鄭敏, 白秋江, 趙軍. 抗癲癇新藥吡侖帕奈. 藥物流行病學雜志. 2013, 22(7): 397-398.
5.	周永, 劉民, 梁萬年. 癲癇流行病學研究進展. 中華流行病學雜志. 2007, 28(1): 92-94.
6.	Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017, 58(Suppl. 1): 522-530.
7.	趙彩紅, 劉友紅, 丁金金, 等. 吡侖帕奈在4~12歲局灶性癲癇患兒中單藥治療的效果及安全性研究. 癲癇與神經電生理學雜志. 2022, 31(5): 289-293.
8.	Krauss GL, Perucca E, Kwan P, et al. Final safety tolerability and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase iii randomized trials: Study 307. Epilepsia, 2018, 59(4): 866-876.
9.	Pina-Garza JE, Rosenfeld W, Saeki K, et al. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: post hoc analysis of six randomized studies. Epilepsy Behav, 2020, 104(Pt A): 106876.
10.	Rektor I, Krauss GL, Inoue Y, et al. Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies. Epilepsia, 2020, 61(7): 1491-1502.
11.	Fogarasi A, Flamini R, Milh M, et al. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to < 12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures. Epilepsia, 2020, 61(1): 125-137.
12.	Chen T, Dai SH, Jiang ZQ, et al. The AMPAR Antagonist perampanel attenuates traumatic brain injury through antioxidative and anti-inflammatory activity. Cell Mol Eurobiol, 2017, 37(1): 43-52.

1. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51(6): 1069-1077.
2. Fergus Rugg-Gunn. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia, 2014, 1: 13-15.
3. JA French, GL Krauss, V Biton, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology, 2012, 79(6): 589-596.
4. 鄭敏, 白秋江, 趙軍. 抗癲癇新藥吡侖帕奈. 藥物流行病學雜志. 2013, 22(7): 397-398.
5. 周永, 劉民, 梁萬年. 癲癇流行病學研究進展. 中華流行病學雜志. 2007, 28(1): 92-94.
6. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia, 2017, 58(Suppl. 1): 522-530.
7. 趙彩紅, 劉友紅, 丁金金, 等. 吡侖帕奈在4~12歲局灶性癲癇患兒中單藥治療的效果及安全性研究. 癲癇與神經電生理學雜志. 2022, 31(5): 289-293.
8. Krauss GL, Perucca E, Kwan P, et al. Final safety tolerability and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase iii randomized trials: Study 307. Epilepsia, 2018, 59(4): 866-876.
9. Pina-Garza JE, Rosenfeld W, Saeki K, et al. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: post hoc analysis of six randomized studies. Epilepsy Behav, 2020, 104(Pt A): 106876.
10. Rektor I, Krauss GL, Inoue Y, et al. Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies. Epilepsia, 2020, 61(7): 1491-1502.
11. Fogarasi A, Flamini R, Milh M, et al. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to < 12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures. Epilepsia, 2020, 61(1): 125-137.
12. Chen T, Dai SH, Jiang ZQ, et al. The AMPAR Antagonist perampanel attenuates traumatic brain injury through antioxidative and anti-inflammatory activity. Cell Mol Eurobiol, 2017, 37(1): 43-52.

Journal of Epilepsy

Clinical study of pirenpanet as add-on therapy for intractable epilepsy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content